Long-Term Data
Confirms EndoPredict Reliability
ESMO Breast 2026: Long-term evidence confirms reproducibility and value of local EndoPredict testing
Published June 2026
New data presented at ESMO Breast 2026 provide robust long-term evidence supporting the reproducibility of EndoPredict in routine clinical practice across decentralised laboratory settings.
The results are based on an 8-year national external quality control program in France (2017–2025), in which EndoPredict was repeatedly evaluated across multiple local routine laboratories under real-world conditions. Using shared reference samples tested over time, the program enabled one of the most comprehensive long-term assessments of inter-laboratory consistency in breast cancer genomic testing.
Across repeated measurements and multiple sites, EndoPredict demonstrated:
- 100% concordance in risk classification (low vs high risk)
- in repeated sample analyses
- High analytical reproducibility of the EPclin score under routine conditions
- Stable molecular score performance over an extended time period
- Consistent model-derived 10-year recurrence risk estimates
- Long-term technical robustness across laboratories and analytical platforms
- Stable gene expression measurements across repeated testing
Importantly, these results reflect performance in routine decentralised laboratory practice, where testing is performed locally as part of standard clinical workflows and continuously monitored through external quality control over time.
Relevance of local testing in clinical practice
Decentralised, locally performed genomic testing offers several practical advantages for healthcare systems and patient care:
- Proximity to the patient, enabling timely access to results and supporting faster clinical decision-making
- Integration into local laboratory infrastructure, allowing testing to be embedded directly within routine care pathways
- Locally controlled quality assurance, supported by structured external quality control programs across sites
- Strengthening of regional laboratory expertise and infrastructure, contributing to the maintenance of highly specialised diagnostic capabilities within healthcare systems
- Reduced logistical burden and improved efficiency by avoiding sample transport to central facilities
In addition, local testing models may contribute to more sustainable healthcare delivery by reducing the need for long-distance sample transport and associated logistics, thereby potentially lowering the overall environmental footprint of diagnostic workflows.
Key takeaways
- New data from ESMO Breast 2026 highlight the long-term reproducibility of EndoPredict in local laboratories.
- An 8-year national quality control program in France shows 100% concordance in risk classification and stable performance of EndoPredict.
- Local genomic testing enhances timely access to results, integrates into care and reduces logistical burdens for healthcare systems.
- EndoPredict testing’s robustness illustrates its reliability in decentralised laboratory networks and routine practice.
- The study reinforces the importance of high-quality genomic testing in improving patient care and sustainability in healthcare.
Conclusion
These data support the robustness and consistency of EndoPredict in real-world diagnostic use and illustrate how high-quality genomic testing can be reliably delivered within decentralised laboratory networks and embedded in routine clinical practice.
References
Lehmann-Che J. et al. High robustness and reproducibility of the genomic signature EndoPredict through quality control programs in France since 2017. ESMO Breast 2026 150eP
Related Pages
EndoPredict
An advanced gene expression test for predicting the risk of distant recurrence in early-stage primary breast cancer.
EndoPredict® for breast cancer treatment
Associate Professor Mirette Saad outlines how EndoPredict supports personalised treatment decisions in ER positive, HER2 negative breast cancer.
Breast Cancer
EndoPredict testing and Somatic Mutation in solid tumours gene panel testing (including PIK3CA) for Breast Cancer.